Post-Traumatic Stress Disorder Pipeline Outlook Report 2025 | DelveInsight

DelveInsight's, "Post-Traumatic Stress Disorder (PTSD) Pipeline Insight, 2025," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Post-Traumatic Stress Disorder (PTSD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Post-Traumatic Stress Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Post-Traumatic Stress Disorder Treatment Landscape. Click here to read more @ Post-Traumatic Stress Disorder Pipeline Outlook- https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Post-Traumatic Stress Disorder Pipeline Report
• In June 2025, COMPASS Pathways announced a study of Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder.
• In June 2025, Otsuka Pharmaceutical Development & Commercialization Inc. announced a study of 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of brexpiprazole + sertraline combination treatment in adult participants with Post-Traumatic Stress Disorder.
• In June 2025, Lykos Therapeutics conducted a study is a randomized, double-blind, dose comparison study with an open-label cross-over segment that will assess the safety and efficacy of MDMA-assisted therapy in veterans with chronic PTSD. Twelve of 24 participants will receive the full dose of 125 mg, six will receive 75 mg and six will receive 30 mg (active placebo dose) of MDMA HCl. An independent rater blind to condition will assess symptoms of PTSD and depression, general quality of life and posttraumatic growth prior to any therapy sessions one month after the second experimental session.
• DelveInsight's Post-Traumatic Stress Disorder pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Post-Traumatic Stress Disorder treatment.
• The leading Post-Traumatic Stress Disorder Companies such as Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck A/S, Bionomics Limited, Alto Neuroscience, Transcend Therapeutics and others.
• Promising Post-Traumatic Stress Disorder Pipeline Therapies such as Sertraline and Risperidone, Balovaptan, Brexpiprazole, Psilocybin, JZP150c, Vortioxetine, NYX-783, BNC210, Orvepitant and others.

Discover groundbreaking developments in Post-Traumatic Stress Disorder Therapies! Gain in-depth knowledge of key Post-Traumatic Stress Disorder clinical trials, emerging drugs, and market opportunities @ Post-Traumatic Stress Disorder Clinical Trials Assessment- https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Post-Traumatic Stress Disorder Emerging Drugs Profile
• TNX-102: Tonix Pharmaceuticals, Inc.
TNX-102 SL is a small, rapidly-disintegrating, under the tongue (sublingual) product candidate containing cyclobenzaprine HCl. The unique patented formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. As a multifunctional agent with potent binding and antagonist activities at the serotonin2A, α1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors, TNX-102 SL is in clinical development and has active IND's as a daily bedtime treatment for fibromyalgia, PTSD, alcohol use disorder and agitation in Alzheimer's disease (AAD). TNX-102 SL for AAD has been designated by the FDA a Fast Track development program. Currently, the drug is in phase III stage for the treatment of post-traumatic stress disorder.

• Methylone (TSND-201): Transcend Therapeutics
Methylone, identified as a rapid-acting neuroplastogen, has been shown to swiftly trigger the expression of neuroplasticity genes, including BDNF, in brain regions associated with the pathophysiology of conditions like PTSD, depression, and other central nervous system disorders. This effect is particularly significant given the challenges posed by PTSD, MDD, and anxiety, which stem from deficiencies in the brain circuitry responsible for emotional learning and processing. Currently, the drug is in Phase II stage of its clinical trial for the treatment of PTSD.

• BXCL501: BioXcel Therapeutics
BXCL501, developed by BioXcel Therapeutics, is an innovative neuroscience clinical asset with a novel mechanism of action targeting symptoms like agitation. This investigational, proprietary, orally dissolving film formulation contains dexmedetomidine, a selective alpha-2 receptor agonist. BXCL501 aims to address stress-related behaviors such as agitation and has shown promising anti-agitation results in various clinical trials across neuropsychiatric disorders. Currently, the drug is in Phase I stage of its clinical trial for the treatment of PTSD.

The Post-Traumatic Stress Disorder Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Post-Traumatic Stress Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Post-Traumatic Stress Disorder Treatment.
• Post-Traumatic Stress Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Post-Traumatic Stress Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Post-Traumatic Stress Disorder market

Stay informed about the Post-Traumatic Stress Disorder pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Post-Traumatic Stress Disorder Unmet Needs- https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Post-Traumatic Stress Disorder Companies
Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck A/S, Bionomics Limited, Alto Neuroscience, Transcend Therapeutics and others.

Post-traumatic stress disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Post-Traumatic Stress Disorder Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Transform your understanding of the Post-Traumatic Stress Disorder Pipeline! See the latest progress in drug development and clinical research @ Post-Traumatic Stress Disorder Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Post-Traumatic Stress Disorder Pipeline Report
• Coverage- Global
• Post-Traumatic Stress Disorder Companies- Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck A/S, Bionomics Limited, Alto Neuroscience, Transcend Therapeutics and others.
• Post-Traumatic Stress Disorder Pipeline Therapies- Sertraline and Risperidone, Balovaptan, Brexpiprazole, Psilocybin, JZP150c, Vortioxetine, NYX-783, BNC210, Orvepitant and others.
• Post-Traumatic Stress Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Post-Traumatic Stress Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Research-Access the Full Post-Traumatic Stress Disorder Pipeline Analysis Today! @ Post-Traumatic Stress Disorder Drugs and Companies- https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.